SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals informs about USFDA inspection

08 Feb 2021 Evaluate

Alembic  Pharmaceuticals has informed that the United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals’ New Injectable Facility (F-3) located at Karkhadi from 29th January 2021 to 6th February 2021. This was a scheduled inspection and at the end of the inspection, the USFDA issued a Form 483 with 5 observations. None of the observations are related to data integrity and are procedural in nature. The Company is preparing the response to the observations, which will be submitted to USFDA shortly. The Company is committed to maintain highest quality standards that meet USFDA standards.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

785.40 8.05 (1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×